SAN DIEGO, Aug. 25 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN), developer of molecular and point-of-care diagnostic products, announced today that it was issued U.S. Patent No. 6,780,584, "Electronic Systems and Component Devices for Macroscopic and Microscopic Molecular Biological Reactions, Analyses and Diagnostics," by the U.S. Patent and Trademark Office. The '584 patent covers the design, development, and capability of an electronic system to carry out and control multi-step and multiplex reactions in macroscopic or microscopic formats. The system described in the patent is at the core of Nanogen's electronic microarray technology, which uses electricity to move and concentrate biological samples in miniature formats for diagnostic applications. The '584 patent covers technology that controls biological reactions by managing the localized concentration of two or more reaction-dependant molecules and their reaction environment. This approach greatly enhances the rate and specificity of the molecular biological reaction, as evidenced by the Nanogen microarray's ability to accelerate molecular binding up to 1,000 times faster than traditional passive methods. The technology described in this broad patent enables control over a wide range of molecular reactions involved in molecular analyses and diagnostics, including nucleic acid hybridizations and amplification, antibody and antigen reactions, and more. "Nanogen's unique approach of integrating sophisticated microelectronics and molecular biology made the NanoChip(R) Electronic Microarray the first to be used in developing fast and accurate molecular diagnostic tests," said Howard C. Birndorf, Nanogen chairman and chief executive officer. "With the issuance of patent '584, Nanogen increases its intellectual property portfolio enabling the continued development and commercialization of advanced diagnostics that provide physicians and patients valuable healthcare information." About Nanogen Nanogen, Inc. develops and commercializes products for the molecular and point-of-care diagnostics markets. The company seeks to establish the unique, open-architecture NanoChip(R) Molecular Biology Workstation and NanoChip(R) Cartridge as the standard platform for the prediction, diagnosis and treatment of genetic and infectious diseases. Nanogen offers Analyte Specific Reagents and related products to research and clinical reference labs for the development of tests for the detection of genetic mutations associated with a variety of diseases, such as cystic fibrosis, Alzheimer's disease, and cardiovascular disease. The company's ten years of research involving nanotechnology may also have future applications in medical diagnostics, biowarfare and other industries. Nanogen's business unit, SynX Pharma, leverages proteomic and biomarker research to offer a line of point-of-care diagnostic tests. For additional information please visit Nanogen's website at www.nanogen.com. Forward-Looking Statement This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by Nanogen will be developed into products, whether Nanogen's NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by Nanogen will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in Nanogen's Form 10-K for the year ended December 31, 2003 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward-looking statements.
SOURCE Nanogen, Inc.